INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT

Core Viewpoint - A class action lawsuit has been filed against Corcept Therapeutics Incorporated, alleging securities fraud and unlawful business practices related to the company's operations [2][4]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Corcept and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until April 21, 2026, to request to be appointed as Lead Plaintiff if they purchased or acquired Corcept securities during the Class Period [2]. Group 2: Stock Performance and Regulatory Issues - On December 31, 2025, Corcept disclosed that the FDA issued a Complete Response Letter regarding the New Drug Application for relacorilant, stating that additional evidence of effectiveness was required [4]. - Following the FDA's announcement, Corcept's stock price dropped by $35.40 per share, or 50.4%, closing at $34.80 per share on the same day [4].